Effects of Calcium Carbonate, Sevelamer Hydrochloride or Pantoprazole on the Pharmacokinetics of Cinacalcet
Authors:
- 17 June 2014
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 34 (8) , 537-544
Abstract
Secondary hyperparathyroidism is a common consequence of chronic kidney disease. Cinacalcet (Sensipar®) is often prescribed in combination to reduce elevated levels of parathyroid hormone, calcium and phosphorus. The objective of this study was to assess the effects of concomitantly administered therapies of calcium carbonate (CaCO3; TUMS®), sevelamer hydrochloride (HCl; Renagel®) and pantoprazole sodium (Protonix®) on the pharmacokinetics and safety of cinacalcet in healthy subjects.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Cinacalcet in Patients with Hyperparathyroidism After Renal TransplantationAmerican Journal of Transplantation, 2008
- Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisNew England Journal of Medicine, 2004
- Bone metabolism and disease in chronic kidney diseaseAmerican Journal of Kidney Diseases, 2003
- The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismKidney International, 2003
- Recent developments in the management of secondary hyperparathyroidismKidney International, 2001
- Pathogenesis of secondary hyperparathyroidismKidney International, 1999
- Antacids RevisitedDrugs, 1999
- Pharmacokinetic Drug Interactions with Anti-Ulcer DrugsClinical Pharmacokinetics, 1998
- Drug Interactions of Lipid-Altering DrugsDrug Safety, 1998
- Comparison of the Effects of Over-the-counter Famotidine and Calcium Carbonate Antacid on Postprandial Gastric Acid1996